ViaCyte, Inc. is a stem cell engineering company dedicated to creating and commercializing cell therapies to treat diabetes. The company's goal is insulin independence without immunosuppression, hypoglycemia, or other diabetes-related complications.

Latest News

Mar 12, 2012
ViaCyte Licenses Technologies to Nestlé Institute of Health Sciences.

Aug 9, 2011
ViaCyte Announces Executive Management Changes

June 15, 2011
ViaCyte Names Michael Scott Vice President, Device Research & Development

May 13, 2011
ViaCyte, Inc., Names Anthony Gringeri Chief Development Officer

April 13, 2011
Cellular Dynamics Licenses Technology from ViaCyte

Other News

Diabetes: Progress and Promise in Stem Cell Research. A video produced by the California Institute for Regenerative Medicine (CIRM) featuring patients with diabetes and Dr. Kevin D’Amour, ViaCyte’s Chief Scientific Officer (CSO), describing the company’s pre-clinical diabetes cell therapy program.